SS
COCP icon

SBI Securities’s Cocrystal Pharma COCP Stock Holding History

SBI Securities’s Portfolio COCP Stock Details COCP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35 Hold
33
– – ﹤0.01% 3746
2026
Q1 		$33 Hold
33
– – ﹤0.01% 3660
2025
Q4 		$32 Sell
33
-1
-3% -$1 ﹤0.01% 3677
2025
Q3 		$43 Buy
34
+1
+3% +$2 ﹤0.01% 3752
2025
Q2 		$49 Hold
33
– – ﹤0.01% 3722
2025
Q1 		$47 Hold
33
– – ﹤0.01% 3668
2024
Q4 		$67 Buy
+33
New +$66 ﹤0.01% 3564

Other funds holding COCP

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return

SBI Securities's COCP Position: Q2 2026 in Review

SBI Securities held its Cocrystal Pharma (COCP) position steady in Q2 2026 at 33 shares worth $35. The position accounts for ﹤0.01% of the portfolio, ranked #3746.

SBI Securities first reported a position in COCP in Q4 2024 and has held it in 7 quarters since. The position peaked at $67 in Q4 2024. 19 funds tracked by Wall St. Rank hold COCP as of Q2 2026.

  • SBI Securities held 33 shares of Cocrystal Pharma worth $35 as of Q2 2026.
  • SBI Securities left its Cocrystal Pharma share count unchanged in Q2 2026.
  • Cocrystal Pharma made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3746 holding.
  • SBI Securities first reported a position in Cocrystal Pharma in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Cocrystal Pharma position peaked at $67 in Q4 2024.
  • 19 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.